Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIVERSAL1: Optimized Dose Ratio of DTG/FTC/TAF in Children with HIV
NCT05993767Phase 2Completed
- Sponsor
- Penta Foundation
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of dolutegravir, emtricitabine, tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Penta Foundation. Started Dec 2024; status: completed.
02
Drugs
dolutegraviremtricitabinetenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05993767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05993767.